Business Context and Reporting Period
This Form 8-K Current Report was filed by Longeveron Inc. (Nasdaq: LGVN) on August 17, 2026. The filing discloses a significant executive leadership change within the company's financial management team.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on personnel appointments and compensation arrangements.
Material Changes
- Appointment of CFO: Nirav S. Jhaveri was appointed as Chief Financial Officer, principal financial officer, and principal accounting officer, effective August 17, 2026.
- Role Transition: Marie Washburn, the outgoing CFO, will remain with the company in her prior role of Vice President and Corporate Controller.
- Compensation Structure: Mr. Jhaveri's compensation package includes:
- Base salary of $400,000 per year.
- Annual cash incentive plan with a target of 45% of base salary.
- Equity award of 300,000 Restricted Stock Units (RSUs) vesting quarterly over three years.
Outlook, Risks, and Management Commentary
The filing highlights Mr. Jhaveri's extensive background, including over 25 years of biopharma and biotech leadership experience. His recent roles include CFO of Opus Genetics, Inc. (2024-2025) and Insilico Medicine (2021-2023). The company states there are no other arrangements or understandings regarding his selection and no material transactions involving him since the beginning of the last fiscal year. No specific risks, contingencies, or forward-looking guidance regarding financial performance are disclosed in this report.
Investor Verification Checklist
- Verify the full text of the Letter Agreement (Exhibit 10.1) for detailed severance and termination provisions.
- Review the attached Press Release (Exhibit 99.1) for additional strategic context regarding the leadership transition.
- Confirm the vesting schedule and performance conditions for the 300,000 RSUs granted to Mr. Jhaveri.
- Monitor future filings for the impact of this leadership change on the company's capital markets strategy and fundraising activities.